Subtype
Uterine Corpus Neoplasm
CI-CAN-00007035Explore in graph →
Non-malignant451 active trials4 approved drugs28 evidence items
- NCIt
- C6300
Loading cancer entity…
Subtype
CI-CAN-00007035Explore in graph →
Clinical trials
1,714 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05554328 | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 165 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY |
| 3 |
| Aug 4, 2026 |
| clinicaltrials |
| NCT07738315 | Elemene Liposomes in Endometrial Cancer | not yet recruiting | Phase 2 | 212 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03526432 | Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer | active not recruiting | Phase 2 | 110 | University of OklahomaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT07737795 | Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer | not yet recruiting | Phase 2 | 66 | University of OklahomaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02912572 | Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer | active not recruiting | Phase 2 | 106 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07731607 | Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer | not yet recruiting | Phase 2 | 48 | Wang JianliuOTHER | 0 | Jul 28, 2026 | clinicaltrials |
| NCT05538897 | Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers | active not recruiting | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06003231 | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | active not recruiting | Phase 2 | 120 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 22, 2026 | clinicaltrials |
| NCT03400826 | Effects of Simvastatin on Uterine Leiomyoma Size | active not recruiting | Phase 2 | 60 | Johns Hopkins UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07714070 | Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia(PKUPH-ORLPP-EC) | not yet recruiting | Phase 2 | 48 | Peking University People's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04469764 | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | recruiting | Phase 2 | 32 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | recruiting | Phase 2 | 270 | Corcept TherapeuticsINDUSTRY | 8 | Jul 16, 2026 | clinicaltrials |
| NCT07209449 | A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer | recruiting | Phase 2 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06129604 | Pilot Window of Opportunity Trial (POET) | active not recruiting | Phase 2 | 10 | University of OklahomaOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07139977 | Study of EV for Recurrent Endometrial Carcinoma(EV-4-EC) | recruiting | Phase 2 | 12 | William BradleyOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT04774419 | Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery | recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07436793 | Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial | recruiting | Phase 2 | 140 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05377996 | A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03832361 | Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer | recruiting | Phase 2 | 50 | Alessandro SantinOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03016338 | Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 51 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03675893 | RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer | recruiting | Phase 2 | 110 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07647198 | FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence(FATIMA) | recruiting | Phase 2 | 240 | Sheikh Shakhbout Medical CityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04251416 | A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma | active not recruiting | Phase 2 | 50 | Yale UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07610798 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations | recruiting | Phase 1 / Phase 2 | 178 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07634601 | Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer | not yet recruiting | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05869123 | Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer | active not recruiting | Phase 1 / Phase 2 | 17 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07107334 | A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07631871 | An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy | not yet recruiting | Phase 2 | 10 | Haihua YuanOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | not yet recruiting | Phase 2 | 15 | Haihua YuanOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT05247268 | Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer | recruiting | Phase 2 | 104 | Fudan UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06914297 | TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC | recruiting | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03671811 | Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy | active not recruiting | Phase 2 | 44 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06730347 | A Study of Lorigerlimab in Participants With Advanced Solid Tumors | recruiting | Phase 2 | 80 | MacroGenicsINDUSTRY | 3 | Jun 2, 2026 | clinicaltrials |
| NCT03835819 | A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) | active not recruiting | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06680739 | Single cEll pRofiling PErsistaNce To ImmuNothErapy(SERPENTINE) | recruiting | Phase 2 | 60 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | active not recruiting | Phase 1 / Phase 2 | 540 | Eli Lilly and CompanyINDUSTRY | 6 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor | recruiting | Phase 1 / Phase 2 | 201 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT03008408 | A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma | active not recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07605247 | Tirzepatide in the Treatment of Endometrial Cancer(TREAT-EC) | not yet recruiting | Phase 2 | 30 | Rutgers, The State University of New JerseyOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT05761951 | Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05255653 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features(RAINBO) | recruiting | Phase 2 / Phase 3 | 1,615 | Leiden University Medical CenterOTHER | 4 | May 15, 2026 | clinicaltrials |
| NCT05979610 | Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies(Reiki-Brachy) | recruiting | Phase 2 | 70 | University of UtahOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06023862 | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)(DOVE) | recruiting | Phase 2 | 198 | Yonsei UniversityOTHER | 7 | May 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 4, 2026source: clinicaltrials